John J. Reddington
Directeur/Membre du Conseil chez 3Brain AG
Profil
John J.
Reddington is currently a Director at 3Brain AG and Grid News Bureau LLC.
Previously, he was the President & Chief Executive Officer at Morris Animal Foundation from 2016 to 2018 and the Chief Operating Officer at Valentis, Inc. from 2003 to 2006.
Reddington received his undergraduate degree from Rice University, his graduate degree from The University of Texas at Austin, and his doctorate from Washington State University.
Postes actifs de John J. Reddington
| Sociétés | Poste | Début |
|---|---|---|
3Brain AG
 3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | Directeur/Membre du Conseil | - |
| Grid News Bureau LLC | Directeur/Membre du Conseil | - |
Anciens postes connus de John J. Reddington
| Sociétés | Poste | Fin |
|---|---|---|
Morris Animal Foundation
 Morris Animal Foundation Miscellaneous Commercial ServicesCommercial Services Morris Animal Foundation operates as an animal health charity. It helps support the advancement of veterinary medicine and funds veterinary research for companion animals, horses, and wildlife. The company was founded by Mark Morris Sr. in 1948 and is headquartered in Denver, CO. | Directeur Général | 01/02/2018 |
Valentis, Inc.
 Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Directeur des opérations | 01/11/2006 |
Formation de John J. Reddington
| Washington State University | Doctorate Degree |
| The University of Texas at Austin | Graduate Degree |
| Rice University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
Morris Animal Foundation
Morris Animal Foundation Miscellaneous Commercial ServicesCommercial Services Morris Animal Foundation operates as an animal health charity. It helps support the advancement of veterinary medicine and funds veterinary research for companion animals, horses, and wildlife. The company was founded by Mark Morris Sr. in 1948 and is headquartered in Denver, CO. | Commercial Services |
3Brain AG
3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | Technology Services |
| Grid News Bureau LLC |
